Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations

References

• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259. doi:10.1056/NEJMoa052256
   PubMed Web of Science ®Google Scholar
• Oren O, Goldberg S. Heart failure with preserved ejection fraction: diagnosis and management. Am J Med. 2017;130:510–516. doi:10.1016/j.amjmed.2016.12.031
   PubMed Web of Science ®Google Scholar
• Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction [published online ahead of print, 2020 Mar 30]. Nat Rev Cardiol. 2020. doi:10.1038/s41569-020-0363-2
   Web of Science ®Google Scholar
• Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550. doi:10.1093/eurheartj/ehm037
   PubMed Web of Science ®Google Scholar
• Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297–3317. doi:10.1093/eurheartj/ehz641
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. doi:10.1002/ejhf.592
   PubMed Web of Science ®Google Scholar
• Seferovic PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the EuropeanSociety of Cardiology. Eur J Heart Fail. 2018;20:853–872. doi:10.1002/ejhf.1170
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Stough WG, Abraham WT, OPTIMIZE‐HF Investigators and Hospitals, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol. 2007;50:768–777. doi:10.1016/j.jacc.2007.04.064
   PubMed Web of Science ®Google Scholar
• Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574–1585. doi:10.1002/ejhf.813
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of comorbiditiesin heart failure. Eur J Heart Fail. 2016;18:744–758. doi:10.1016/j.ijcard.2018.04.001
   PubMed Web of Science ®Google Scholar
• Beale AL, Meyer P, Marwick TH, et al. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation. 2018;138:198–205. doi:10.1161/CIRCULATIONAHA.118.034271
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321–1360. doi:10.1016/j.echo.2016.01.011
   PubMed Web of Science ®Google Scholar
• Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2019. doi:10.1002/clc.23321
   Web of Science ®Google Scholar
• Cikes M, Solomon SD. Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur Heart J. 2016;37:1642‐1650. doi:10.1093/eurheartj/ehv510
   PubMed Web of Science ®Google Scholar
• Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep. 2015;12(4):276–283. doi:10.1007/s11897-015-0261-9
   PubMedGoogle Scholar
• Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR working group of the european society of cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92. doi:10.1186/1532-429X-15-92
   PubMed Web of Science ®Google Scholar
• Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the american college of cardiology foundation task force on expert consensus documents. Circulation. 2010;121(22):2462–2508. doi:10.1161/CIR.0b013e3181d44a8f
   PubMed Web of Science ®Google Scholar
• Kraigher-Krainer E, Shah AM, Gupta DK, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(5):447‐456. doi:10.1016/j.jacc.2013.09.052
   PubMed Web of Science ®Google Scholar
• Ito H, Ishida M, Makino W, et al. Cardiovascular magnetic resonance feature tracking for characterization of patients with heart failure with preserved ejection fraction: correlation of global longitudinal strain with invasive diastolic functional indices. J Cardiovasc Magn Reson. 2020;22(1):42. doi:10.1186/s12968-020-00636-w
   PubMed Web of Science ®Google Scholar
• Leng S, Tan RS, Zhao X, Allen JC, Koh AS, Zhong L. Validation of a rapid semi-automated method to assess left atrial longitudinal phasic strains on cine cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson. 2018;20(1):71. doi:10.1186/s12968-018-0496-1
   PubMed Web of Science ®Google Scholar
• Leng S, Tan RS, Zhao X, Allen JC, Koh AS, Zhong L. Fast long-axis strain: a simple, automatic approach for assessing left ventricular longitudinal function with cine cardiovascular magnetic resonance. Eur Radiol. 2020. doi:10.1007/s00330-020-06744-6
   PubMed Web of Science ®Google Scholar
• Schuster A, Hor KN, Kowallick JT, Beerbaum P, Kutty S. Cardiovascular magnetic resonance myocardial feature tracking: concepts and clinical applications. Circ Cardiovasc Imaging. 2016;9(4):e004077. doi:10.1161/CIRCIMAGING.115.004077
   PubMed Web of Science ®Google Scholar
• Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-la Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):413–421. doi:10.1002/ejhf.1614
   PubMed Web of Science ®Google Scholar
• Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA, Simple A. Evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138(9):861‐870. doi:10.1161/CIRCULATIONAHA.118.034646
   Web of Science ®Google Scholar
• Segar MW, Patel KV, Berry JD, Grodin JL, Pandey A. Generalizability and implications of the H2FPEF score in a cohort of patients with heart failure with preserved ejection fraction. Circulation. 2019;139(15):1851‐1853. doi:10.1161/CIRCULATIONAHA.118.039051
   PubMed Web of Science ®Google Scholar
• Myhre PL, Vaduganathan M, Claggett BL, et al. Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail. 2019;21(10):1288‐1291. doi:10.1002/ejhf.1542
   Web of Science ®Google Scholar
• Suzuki S, Kaikita K, Yamamoto E, et al. H2 FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors. ESC Heart Fail. 2020;7(1):65–74. doi:10.1002/ehf2.12570
   PubMed Web of Science ®Google Scholar
• Takahari K, Hidaka T, Ueda Y, et al. H2FPEF score for the prediction of exercise intolerance and abnormal hemodynamics in japanese- evaluation by exercise stress echocardiography combined with cardiopulmonary exercise testing. Circ J. 2019;83(12):2487–2493. doi:10.1253/circj.CJ-19-0699
   PubMed Web of Science ®Google Scholar
• Del Buono MG, Iannaccone G, Scacciavillani R, et al. Heart failure with preserved ejection fraction diagnosis and treatment: an updated review of the evidence. Prog Cardiovasc Dis. 2020;S0033-0620(20):30083–30089. doi:10.1016/j.pcad.2020.04.011
   Web of Science ®Google Scholar
• Jain CC, Borlaug BA. Performance and interpretation of invasive hemodynamic exercise testing. Chest. 2020;S0012–3692(20):31617–31620. doi:10.1016/j.chest.2020.05.552
   Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239. doi:10.1016/j.jacc.2013.05.019
   PubMed Web of Science ®Google Scholar
• Burgess MI, Jenkins C, Sharman JE, et al. Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of ventricular filling pressure with exercise. J Am Coll Cardiol. 2006;47(9):1891–1900. doi:10.1016/j.jacc.2006.02.042
   PubMed Web of Science ®Google Scholar
• Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588–595. doi:10.1161/CIRCHEARTFAILURE.109.930701
   PubMed Web of Science ®Google Scholar
• Flachskampf F, Biering-Sørensen T, Solomon S, et al. Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging. 2015;8:1071–1093. doi:10.1016/j.jcmg.2015.07.004
   PubMed Web of Science ®Google Scholar
• Hammoudi N, Laveau F, Helft G, et al. Low level exercise echocardiography helps diagnose early stage heart failure with preserved ejection fraction: a study of echocardiography versus catheterization. Clin Res Cardiol. 2017;106(3):192–201. doi:10.1007/s00392-016-1039-0
   PubMed Web of Science ®Google Scholar
• Obokata M, Kane GC, Reddy YN, et al. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825–838. doi:10.1161/CIRCULATIONAHA.116.024822
   PubMed Web of Science ®Google Scholar
• Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–870. doi:10.1161/CIRCULATIONAHA.118.034646
   PubMed Web of Science ®Google Scholar
• Lundberg A, Johnson J, Hage C, et al. Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. Clin Res Cardiol. 2018. doi:10.1007/s00392-018-1399-8
   PubMed Web of Science ®Google Scholar
• Kasner M, Sinning D, Lober J, et al. Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction. ESC Heart Failure. 2015;2:121–132. doi:10.1002/ehf2.12049
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Pellikka PA, Budts W, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2016;17:1191–1229. doi:10.1093/ehjci/jew190
   PubMed Web of Science ®Google Scholar
• Erdei T, Smiseth OA, Marino P, et al. A systematic review of diastolic stress test in heart failure with preserved ejection fraction, with proposals from EU-FP7 MEDIA study group. Eur J Heart Fail. 2014;16:1345–1361. doi:10.1002/ejhf.184
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Bandera F, Generati G, et al. Left atrial dynamics during exercise in mitral regurgitation of primary and secondary origin: pathophysiological insights by exercise echocardiography combined with gas exchange analysis. JACC Cardiovasc Imaging. 2019;S1936-878X(19):30162–30167. doi:10.1016/j.jcmg.2018.12.031
   Web of Science ®Google Scholar
• Morris DA, Takeuchi M, Nakatani S, et al. Lower limit of normality and clinical relevance of left ventricular early diastolic strain rate for the detection of left ventricular diastolic dysfunction. Eur Heart J Cardiovasc Imaging. 2018;19(8):905–915. doi:10.1093/ehjci/jex185
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Chang SM, Nabi F, et al. Cardiac imaging in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging. 2017;10:e006547.
   PubMed Web of Science ®Google Scholar
• Belyavskiy E, Morris DA, Url-Michitsch M, et al. Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. ESC Heart Fail. 2019;6(1):146–153. doi:10.1002/ehf2.12375
   PubMed Web of Science ®Google Scholar
• Chen SM, He R, Li WH, et al. Relationship between exercise induced elevation of left ventricular filling pressure and exercise intolerance in patients with atrial fibrillation. J Geriatr Cardiol. 2016;13:546–551. doi:10.11909/j.issn.1671-5411.2016.06.016
   PubMedGoogle Scholar
• Morris DA, Boldt LH, Eichstädt H, Ozcelik C, Haverkamp W. Myocardial systolic and diastolic performance derived by 2-dimensional speckle tracking echocardiography in heart failure with normal left ventricular ejection fraction. Circ Heart Fail. 2012;5(5):610‐620. doi:10.1161/CIRCHEARTFAILURE.112.966564
   Web of Science ®Google Scholar
• Morris DA, Ma XX, Belyavskiy E, et al. Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017;4(2):e000630. doi:10.1136/openhrt-2017000630
   PubMed Web of Science ®Google Scholar
• Zhong L, Poh KK, Lee LC, Le TT, Tan RS. Attenuation of stress-based ventricular contractility in patients with heart failure and normal ejection fraction. Ann Acad Med Singapore. 2011;40:179‐185.
   PubMed Web of Science ®Google Scholar
• Zhong L, Ng KK, Sim LL, et al. Myocardial contractile dysfunction associated with increased 3-month and 1-year mortality in hospitalized patients with heart failure and preserved ejection fraction. Int J Cardiol. 2013;168(3):1975‐1983. doi:10.1016/j.ijcard.2012.12.084
   Web of Science ®Google Scholar
• Obokata M, Reddy YNV, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):245‐257. doi:10.1016/j.jcmg.2018.12.034
   PubMed Web of Science ®Google Scholar
• Telles F, Marwick TH. Imaging and management of heart failure and preserved ejection fraction. Curr Treat Options Cardiovasc Med. 2018;20(11):90. doi:10.1007/s11936-018-0689-9
   PubMedGoogle Scholar
• Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54(5):410‐418. doi:10.1016/j.jacc.2009.05.013
   PubMed Web of Science ®Google Scholar
• Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015;132:402–414. doi:10.1161/CIRCULATIONAHA.115.015884
   PubMed Web of Science ®Google Scholar
• Morris DA, Gailani M, Vaz Pérez A, et al. Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. J Am Soc Echocardiogr. 2011;24(6):651–662. doi:10.1016/j.echo.2011.02.004
   PubMed Web of Science ®Google Scholar
• Freed BH, Daruwalla V, Cheng JY, et al. Prognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strain. Circ Cardiovasc Imaging. 2016;9(3):e003754. doi:10.1161/CIRCIMAGING.115.003754
   PubMed Web of Science ®Google Scholar
• Morris DA, Belyavskiy E, Aravind-Kumar R, et al. Potential usefulness and clinical relevance of adding left atrial strain to left atrial volume index in the detection of left ventricular diastolic dysfunction. JACC Cardiovasc Imaging. 2018;11(10):1405–1415. doi:10.1016/j.jcmg.2017.07.029
   PubMed Web of Science ®Google Scholar
• Braunauer K, Pieske-Kraigher E, Belyavskiy E, et al. Early detection of cardiac alterations by left atrial strain in patients with risk for cardiac abnormalities with preserved left ventricular systolic and diastolic function. Int J Cardiovasc Imaging. 2018;34(5):701–711. doi:10.1007/s10554-017-1280-2
   PubMed Web of Science ®Google Scholar
• Santos AB, Kraigher-Krainer E, Gupta DK, et al. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;16(10):1096–1103. doi:10.1002/ejhf.147
   PubMed Web of Science ®Google Scholar
• Santos AB, Roca GQ, Claggett B, et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(4):e002763. doi:10.1161/CIRCHEARTFAILURE.115.002763
   PubMed Web of Science ®Google Scholar
• Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49(2):198–207. doi:10.1016/j.jacc.2006.08.050
   PubMed Web of Science ®Google Scholar
• Melenovsky V, Hwang SJ, Redfield MM, Zakeri R, Lin G, Borlaug BA. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail. 2015;8(2):295‐303. doi:10.1161/CIRCHEARTFAILURE.114.001667
   Web of Science ®Google Scholar
• Mandoli GE, Sisti N, Mondillo S, Cameli M. Left atrial strain in left ventricular diastolic dysfunction: have we finally found the missing piece of the puzzle? Heart Fail Rev. 2020;25(3):409–417. doi:10.1007/s10741-019-09889-9
   PubMed Web of Science ®Google Scholar
• Khan MS, Memon MM, Murad MH, et al. Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail. 2020;22(3):472‐485. doi:10.1002/ejhf.1643
   Web of Science ®Google Scholar
• Magaña-Serrano JA, Almahmeed W, Gomez E, et al. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study). Am J Cardiol. 2011;108(9):1289‐1296. doi:10.1016/j.amjcard.2011.06.044
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124(11):1598‐1617. doi:10.1161/CIRCRESAHA.119.313572
   PubMed Web of Science ®Google Scholar
• Brown DW, Haldeman GA, Croft JB, Giles WH, Mensah GA. Racial or ethnic differences in hospitalization for heart failure among elderly adults: medicare, 1990 to 2000. Am Heart J. 2005;150(3):448–454. doi:10.1016/j.ahj.2004.11.010
   PubMed Web of Science ®Google Scholar
• Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168(19):2138‐2145. doi:10.1001/archinte.168.19.2138
   PubMedGoogle Scholar
• Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB. Racial differences in incident heart failure during antihypertensive therapy. Circ Cardiovasc Qual Outcomes. 2011;4(2):157‐164. doi:10.1161/CIRCOUTCOMES.110.960112
   PubMed Web of Science ®Google Scholar
• Eaton CB, Abdulbaki AM, Margolis KL, et al. Racial and ethnic differences in incident hospitalized heart failure in postmenopausal women: the Women’s Health Initiative. Circulation. 2012;126(6):688‐696. doi:10.1161/CIRCULATIONAHA.111.066688
   Web of Science ®Google Scholar
• Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340(8):609‐616. doi:10.1056/NEJM199902253400804
   PubMed Web of Science ®Google Scholar
• East MA, Peterson ED, Shaw LK, Gattis WA, O’Connor CM. Racial differences in the outcomes of patients with diastolic heart failure. Am Heart J. 2004;148(1):151‐156. doi:10.1016/j.ahj.2004.01.017
   PubMed Web of Science ®Google Scholar
• Gupta DK, Shah AM, Castagno D, et al. Heart failure with preserved ejection fraction in African Americans: the ARIC (Atherosclerosis Risk In Communities) study. JACC Heart Fail. 2013;1(2):156‐163. doi:10.1016/j.jchf.2013.01.003
   Web of Science ®Google Scholar
• Tromp J, Teng TH, Tay WT, et al. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019;21(1):23‐36. doi:10.1002/ejhf.1227
   Web of Science ®Google Scholar
• Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118(8):1273‐1293. doi:10.1161/CIRCRESAHA.116.307547
   PubMed Web of Science ®Google Scholar
• Tadic M, Cuspidi C, Plein S, Belyavskiy E, Heinzel F, Galderisi M. Sex and heart failure with preserved ejection fraction: from pathophysiology to clinical studies. J Clin Med. 2019;8(6):792. doi:10.3390/jcm8060792
   PubMed Web of Science ®Google Scholar
• Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol. 2000;86(10):1090‐1096. doi:10.1016/s0002-9149(00)01165-6
   PubMed Web of Science ®Google Scholar
• Lundorff IJ, Sengeløv M, Godsk Jørgensen P, et al. Echocardiographic predictors of mortality in women with heart failure with reduced ejection fraction. Circ Cardiovasc Imaging. 2018;11(11):e008031. doi:10.1161/CIRCIMAGING.118.008031
   PubMed Web of Science ®Google Scholar
• Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J. 2019;40(47):3859‐3868c. doi:10.1093/eurheartj/ehz835
   Web of Science ®Google Scholar
• Wolsk E, Kaye D, Komtebedde J, et al. Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction. JACC Heart Fail. 2019;7(4):321‐332. doi:10.1016/j.jchf.2019.01.006
   Web of Science ®Google Scholar
• Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure and a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail. 2020. doi:10.1002/ejhf.1902
   Web of Science ®Google Scholar
• Donal E, Lund LH, Oger E; KaRen Investigators, et al. Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging. 2017;18:629–635. doi:10.1093/ehjci/jex005
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K; CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777–781. doi:10.1016/S0140-6736(03)14285-7
   PubMed Web of Science ®Google Scholar
• Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–2467. doi:10.1056/NEJMoa0805450
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345. doi:10.1056/NEJMoa0805450
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJS; SENIORS Investigators, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225. doi:10.1093/eurheartj/ehi115
   PubMed Web of Science ®Google Scholar
• Mulder BA, van Veldhuisen DJ, Crijns HJGM, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail. 2012;14:1171–1178. doi:10.1093/eurjhf/hfs100
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2009;53:2150–2158. doi:10.1016/j.jacc.2009.02.046
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–1678. doi:10.1093/europace/euw295
   PubMed Web of Science ®Google Scholar
• Rattka M, Pott A, Kühberger A, et al. Restoration of sinus rhythm by pulmonary vein isolation improves heart failure with preserved ejection fraction in atrial fibrillation patients. Europace. 2020:euaa101. doi:10.1093/europace/euaa101.
   Web of Science ®Google Scholar
• Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–1274. doi:10.1001/jama.2019.0693
   PubMed Web of Science ®Google Scholar
• Obokata M, Reddy YNV, Melenovsky V, et al. Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2018;72(1):29–40. doi:10.1016/j.jacc.2018.04.039
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(25Pt A):2817–2827. doi:10.1016/j.jacc.2014.03.034
   PubMed Web of Science ®Google Scholar
• Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397–403. doi:10.1161/CIRCULATIONAHA.106.628347
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392. doi:10.1056/NEJMoa1313731
   PubMed Web of Science ®Google Scholar
• Morris JH, Chen L. Exercise training and heart failure: a review of the literature. Card Fail Rev. 2019;5:57–61. doi:10.15420/cfr.2018.31.1
   PubMedGoogle Scholar
• Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8:33–40. doi:10.1161/CIRCHEARTFAILURE.114.001615
   PubMed Web of Science ®Google Scholar
• Solomon SD, JJV M, Anand IS, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–1620. doi:10.1056/NEJMoa1908655
   PubMed Web of Science ®Google Scholar
• Nassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019;Suppl 2(S2):19–23. doi:10.1111/dom.13678
   Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-preserved trial. Eur J Heart Fail. 2019;21:1279–1287. doi:10.1002/ejhf.1596
   PubMed Web of Science ®Google Scholar
• Wintrich J, Kindermann I, Ukena C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future [published online ahead of print, 2020 Mar 31]. Clin Res Cardiol. 2020. doi:10.1007/s00392-020-01633-w
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808–817. doi:10.1093/eurjhf/hft050
   PubMed Web of Science ®Google Scholar
• Sandhu AT, Heidenreich PA. Heart failure management with ambulatory pulmonary artery pressure monitoring. Trends Cardiovasc Med. 2018;28(3):212–219. doi:10.1016/j.tcm.2017.09.002
   PubMed Web of Science ®Google Scholar
• Abraham WT, Perl L. Implantable hemodynamic monitoring for heart failure patients. J Am Coll Cardiol. 2017;70(3):389–398. doi:10.1016/j.jacc.2017.05.052
   PubMed Web of Science ®Google Scholar
• Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–666. doi:10.1016/S0140-6736(11)60101-3
   PubMed Web of Science ®Google Scholar
• Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016;387(10017):453–461. doi:10.1016/S0140-6736(15)00723-0
   PubMed Web of Science ®Google Scholar
• Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–944. doi:10.1161/CIRCHEARTFAILURE.113.001229
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Abraham WT, Maisel A, et al. Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). Am Heart J. 2019;214:18–27. doi:10.1016/j.ahj.2019.04.014
   PubMed Web of Science ®Google Scholar
• Hasenfuß G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, Phase 1 trial. Lancet. 2016;387(10025):1298–1304. doi:10.1016/S0140-6736(16)00704-2
   PubMed Web of Science ®Google Scholar
• Feldman T, Komtebedde J, Burkhoff D, et al. Transcatheter interatrial shunt device for the treatment of heart failure: rationale and design of the randomized trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). Circ Heart Fail. 2016;9(7):e003025. doi:10.1161/CIRCHEARTFAILURE.116.003025
   PubMed Web of Science ®Google Scholar
• Shah SJ, Feldman T, Ricciardi MJ, et al. One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol. 2018;3(10):968–977. doi:10.1001/jamacardio.2018.2936
   PubMed Web of Science ®Google Scholar
• Obokata M, Reddy Yogesh NV, Shah SJ, et al. Effects of interatrial shunt on pulmonary vascular function in heartfailure with preserved ejection fraction. J Am Coll Cardiol. 2019;74(21):2539–2550. doi:10.1016/j.jacc.2019.08.1062
   PubMed Web of Science ®Google Scholar
• Kaye DM, Petrie MC, McKenzie S, et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail. 2019;6(1):62–69. doi:10.1002/ehf2.12350
   PubMed Web of Science ®Google Scholar
• Kaye DM, Nanayakkara S. Interatrial shunt device for heart failure with preserved ejection fraction. Front Cardiovasc Med. 2019;6:143. doi:10.3389/fcvm.2019.00143
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Lüscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34(28):2149–2157. doi:10.1093/eurheartj/eht154
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–1281. doi:10.1016/S0140-6736(09)60566-3
   PubMed Web of Science ®Google Scholar
• Donazzan L, Mahfoud F, Ewen S, et al. Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clin Res Cardiol. 2016;105(4):364–371. doi:10.1007/s00392-015-0930-4
   PubMed Web of Science ®Google Scholar
• Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–909. doi:10.1016/j.jacc.2011.11.034
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Urban D, Teller D, et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J. 2014;35(33):2224–31b. doi:10.1093/eurheartj/ehu093
   PubMed Web of Science ®Google Scholar
• Schirmer SH, Sayed MM, Reil JC, et al. Atrial remodeling following catheter-based renal denervation occurs in a blood pressure- and heart rate-independent manner. JACC Cardiovasc Interv. 2015;8(7):972–980. doi:10.1016/j.jcin.2015.02.014
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Böhm M, Azizi M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–2227. doi:10.1093/eurheartj/ehv192
   PubMed Web of Science ®Google Scholar
• Patel HC, Rosen SD, Hayward C, et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail. 2016;18(6):703–712. doi:10.1002/ejhf.502
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–1401. doi:10.1056/NEJMoa1402670
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355. doi:10.1016/S0140-6736(18)30951-6
   PubMed Web of Science ®Google Scholar
• Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451. doi:10.1016/S0140-6736(20)30554-7
   PubMed Web of Science ®Google Scholar
• Weber MA, Mahfoud F, Schmieder RE, et al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv. 2019;12(12):1095–1105. doi:10.1016/j.jcin.2019.02.050
   PubMed Web of Science ®Google Scholar
• Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269–279. doi:10.1161/CIRCULATIONAHA.114.010637
   PubMed Web of Science ®Google Scholar
• Obokata M, Reddy YNV, Borlaug BA. The role of echocardiography in heart failure with preserved ejection fraction: what do we want from imaging? Heart Fail Clin. 2019;15(2):241–256. doi:10.1016/j.hfc.2018.12.004
   PubMed Web of Science ®Google Scholar
• Harada T, Obokata M. Obesity-related heart failure with preserved ejection fraction: pathophysiology, diagnosis, and potential therapies. Heart Fail Clin. 2020;16(3):357–368. doi:10.1016/j.hfc.2020.02.004
   PubMed Web of Science ®Google Scholar
• Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6–19. doi:10.1161/CIRCULATIONAHA.116.026807
   PubMed Web of Science ®Google Scholar
• Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119–1126. doi:10.1016/j.jacc.2008.11.051
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119. doi:10.1093/eurheartj/ehv317
   PubMed Web of Science ®Google Scholar
• Vachiéry JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53:1801897. doi:10.1183/13993003.01897-2018
   PubMed Web of Science ®Google Scholar
• Melenovsky V, Hwang SJ, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3452–3462. doi:10.1093/eurheartj/ehu193
   PubMed Web of Science ®Google Scholar
• Gorter TM, van Veldhuisen DJ, Bauersachs J, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(1):16–37. doi:10.1002/ejhf.1029
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Lam CSP, Vachiery JL, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. Eur Heart J. 2017;38(38):2869–2873. doi:10.1093/eurheartj/ehw597
   PubMed Web of Science ®Google Scholar
• Borlaug BA, Obokata M. Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease. Eur Heart J. 2017;38(38):2874–2878. doi:10.1093/eurheartj/ehx184
   PubMed Web of Science ®Google Scholar
• Gorter TM, Obokata M, Reddy YNV, Melenovsky V, Borlaug BA. Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur Heart J. 2018;39(30):2825–2835. doi:10.1093/eurheartj/ehy331
   PubMed Web of Science ®Google Scholar